Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | LTB4R | Q15722 | 3/20 | 0.40 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30769482 | 0.86 | MAOB (0.46) | LMNAL3MBTL1MAOBBACE1 | |
| SCHEMBL30768868 | 0.80 | MAOB (0.41) | NPC1RAB9ALMNAL3MBTL1MAOB | |
| SCHEMBL30769423 | 0.80 | RAB9A (0.47) | NPC1RAB9AL3MBTL1ALOX5MAOB | |
| SCHEMBL30768756 | 0.77 | ALOX5AP (0.39) | LMNAL3MBTL1ALOX5MAOBBACE1 | |
| SCHEMBL30768511 | 0.74 | MAOB (0.50) | RAB9ALMNAL3MBTL1ALOX5MAOB | |
| SCHEMBL1805526 | 0.74 | ALOX5 (0.56) | RAB9ALMNAL3MBTL1ALOX5MAOB | |
| SCHEMBL7385585 | 0.72 | MAOB (0.50) | RAB9ALMNAL3MBTL1ALOX5MAOB | |
| SCHEMBL25316002 | 0.71 | MAOB (0.53) | RAB9ALMNAL3MBTL1ALOX5MAOB | |
| SCHEMBL31383943 | 0.71 | SLC6A2 (0.38) | RAB9ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2353230 | 0.71 | ALOX5 (0.76) | NPC1RAB9AL3MBTL1ALOX5MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-12-25 | — | — | US | disclosed |
| EP-4543871-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| WO-2024006781-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | ESRRA, ESRRB, ESR2 | NPC1 1388/4885RAB9A 4064/4885LMNA 2092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.